Page 98 - Read Online

Thomas et al. J Transl Genet Genom 2024;8:249-77 https://dx.doi.org/10.20517/jtgg.2024.15 Page 275

217. Zhang G, Luo Y. An immune-related lncRNA signature to predict the biochemical recurrence and immune landscape in prostate
cancer. Int J Gen Med 2021;14:9031-49. DOI PubMed PMC
218. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI PubMed
219. Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-dependent methylglyoxal depletion sustains PD-L1
expression in metastatic prostate cancer cells: a novel mechanism in cancer immunosurveillance escape and a potential novel target to
overcome PD-L1 blockade resistance. Cancers 2021;13:2965. DOI PubMed PMC
220. Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy:
emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book 2019;39:165-74. DOI PubMed PMC
221. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate
cancer. Cancers 2022;14:503. DOI PubMed PMC
222. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer
with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76. DOI PubMed
223. Sardinha M, Palma Dos Reis AF, Barreira JV, Fontes Sousa M, Pacey S, Luz R. Antibody-drug conjugates in prostate cancer: a
systematic review. Cureus 2023;15:e34490. DOI PubMed PMC
224. Kamat NV, Yu EY, Lee JK. BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin Cancer Res 2021;27:2675-7. DOI
PubMed PMC
225. Yang K, Feng S, Luo Z. Oncolytic adenovirus, a new treatment strategy for prostate cancer. Biomedicines 2022;10:3262. DOI
PubMed PMC
226. Pieczonka CM, Telonis D, Mouraviev V, Albala D. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant
prostate cancer: considerations for clinical practice. Rev Urol 2015;17:203-10. PubMed PMC
227. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med
2010;363:411-22. DOI
228. Donninger H, Li C, Eaton JW, Yaddanapudi K. Cancer vaccines: promising therapeutics or an unattainable dream. Vaccines
2021;9:668. DOI PubMed PMC
229. Chen S, Wainwright DA, Wu JD, et al. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 2019;11:983-97.
DOI PubMed PMC
230. Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH. The role of indoleamine 2, 3-dioxygenase in immune
suppression and autoimmunity. Vaccines 2015;3:703-29. DOI PubMed PMC
231. Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: the biological processes that motivate targeting this immune checkpoint
molecule in human cancer. Cancers 2019;11:1213. DOI PubMed PMC
232. Miller RA, Luke JJ, Hu S, et al. Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution
of B cells in patients with cancer. J Immunother Cancer 2022;10:e005802. DOI PubMed PMC
233. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-
4 blockade in cancer immunotherapy. J Exp Med 2014;211:715-25. DOI PubMed PMC
234. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta
Pharm Sin B 2020;10:414-33. DOI PubMed PMC
235. Ye L, Jia K, Wang L, et al. CD137, an attractive candidate for the immunotherapy of lung cancer. Cancer Sci 2020;111:1461-7. DOI
PubMed PMC
236. Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune
regulation. Immunol Res 2013;57:197-209. DOI PubMed PMC
237. Schepisi G, Cursano MC, Casadei C, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother
Cancer 2019;7:258. DOI PubMed PMC
238. Patel S, Burga RA, Powell AB, et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. front oncol
2019;9:196. DOI PubMed PMC
239. Mills JK, Henderson MA, Giuffrida L, et al. Generating CAR T cells from tumor-infiltrating lymphocytes. Ther Adv Vaccines
Immunother 2021;9:25151355211017119. DOI PubMed PMC
240. Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther
2022;7:95. DOI PubMed PMC
241. Day KC, Lorenzatti Hiles G, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer
to bone. Cancer Res 2017;77:74-85. DOI PubMed PMC
242. Hsu EC, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Proc Natl Acad Sci USA 2020;117:2032-42. DOI PubMed PMC
243. Rosellini M, Santoni M, Mollica V, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci 2021;22:1551. DOI
PubMed PMC
244. Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J
Hematol Oncol 2021;14:75. DOI PubMed PMC
245. Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther
2023;8:156. DOI PubMed PMC
246. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product